Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study

Table 4

Hazard ratios and 95% confidence intervals for GI cancer for lipid components as continuous variables and based on cut-off points used in cardiovascular disease prevention, stratified by glucose levels, adjusted for age, gender, SES, fasting status, glucose (continuous), total cholesterol (continuous), and triglycerides (continuous).

	Oesophageal cancer		Stomach cancer		Colon cancer		Rectal cancer
	𝑛	HR (95% CI)	𝑛	HR (95% CI)	𝑛	HR (95% CI)	𝑛	HR (95% CI)
Glucose < 6.11 mmol/L
Total cholesterol (mmol/L)^a
Unit increase in log		0.53 (0.28–1.02)		1.00 (0.65–1.53)		1.05 (0.83–1.34)		1.75 (1.29–2.38)
<6.50	192	1.00 (Ref)	463	1.00 (Ref)	1483	1.00 (Ref)	889	1.00 (Ref)
≥6.50	79	0.89 (0.68–1.18)	223	1.03 (0.87–1.22)	735	1.00 (0.91–1.10)	464	1.15 (1.02–1.29)
Triglycerides (mmol/L)^b
Unit increase in log		1.62 (1.28–2.05)		1.08 (0.92–1.26)		1.19 (1.09–1.30)		0.97 (0.87–1.09)
<1.71	193	1.00 (Ref)	521	1.00 (Ref)	1678	1.00 (Ref)	1044	1.00 (Ref)
≥1.71	78	1.38 (1.05–1.83)	165	1.07 (0.89–1.28)	540	1.16 (1.05–1.29)	309	0.98 (0.86–1.12)
Glucose ≥ 6.11 mmol/L
Total cholesterol (mmol/L)^a
Unit increase in log		1.02 (0.23–4.47)		0.68 (0.23–2.05)		1.26 (0.65–2.45)		2.79 (1.19–6.56)
<6.50	32	1.00 (Ref)	60	1.00 (Ref)	164	1.00 (Ref)	83	1.00 (Ref)
≥6.50	15	0.90 (0.70–1.15)	30	1.04 (0.66–1.64)	90	1.01 (0.77–1.32)	74	1.73 (1.25–2.40)
Triglycerides (mmol/L)^b
Unit increase in log		1.59 (0.98–2.60)		0.95 (0.65–1.38)		1.17 (0.93–1.46)		1.11 (0.84–1.47)
<1.71	21	1.00 (Ref)	48	1.00 (Ref)	124	1.00 (Ref)	73	1.00 (Ref)
≥1.71	26	1.27 (0.69–2.32)	42	0.96 (0.62–1.48)	130	1.20 (0.93–1.55)	84	1.15 (0.83–1.60)

^aNot adjusted for TC.
^bNot adjusted for TG.